Becaplermin (Regranex) for Diabetic Foot Ulcers
Courtney I. Jarvis
Abstract
Courtney I. Jarvis
Abstract
Although patients treated with becaplermin are more likely to experience complete and faster ulcer healing than patients continuing good wound care alone, the increased risk of cancer mortality and significant cost outweigh the possible benefits in most patients.
OpenAlex reports 6 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Although patients treated with becaplermin are more likely to experience complete and faster ulcer healing than patients continuing good wound care alone, the increased risk of cancer mortality and significant cost outweigh the possible benefits in most patients.
Key concepts: Medicine, Diabetic foot, Diabetic foot ulcer, Wound care, Intensive care medicine, Diabetic ulcers, Foot (prosody), Surgery